# Tolerance and Pharmacokinetics of TQB2450

> **NCT03460457** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** TQB2450

## Key facts

- **NCT ID:** NCT03460457
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-15
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460457, "Tolerance and Pharmacokinetics of TQB2450". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03460457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*